v3.26.1
License Arrangements - Additional Information (Details) - USD ($)
 1 Months Ended
Apr. 21, 2023
Jan. 31, 2019
Jan. 31, 2016
Jun. 30, 2026
Dec. 31, 2018
Aevitas Therapeutics, Inc. Agreement          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Potential cash payment for development milestones $ 7,200,000        
Potential cash payment for regulatory milestones 68,000,000        
Potential cash payment for sales milestones 68,900,000        
Upfront consideration payment 0        
Liability related to contingent consideration       $ 0  
Aevitas Therapeutics, Inc. Agreement | Maximum          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Potential cash payment upon achievement of certain late-stage milestones 144,100,000        
License Agreement for sCFH with University of Pennsylvania          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Potential cash payment for development milestones 1,900,000        
Potential cash payment for regulatory milestones 21,500,000        
Potential cash payment for sales milestones 18,200,000        
License Agreement for sCFH with University of Pennsylvania | Maximum          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Potential cash payment upon achievement of certain late-stage milestones $ 41,600,000        
UC Agreements          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Liability related to contingent consideration       $ 0  
Non-refundable license fee payable upon execution         $ 5,000
Non-refundable license fee payable upon execution every year thereafter until sales of a licensed product and payment of royalties         5,000
Amount obligated to pay upon closing first qualified financing at option of UC Regents         $ 50,000
Percentage of equity interest upon closing of first qualified financing at option of UC Regents         3.00%
Percentage of equity interests issued as common stock     6.00%    
Amount paid non-refundable license fee   $ 50,000      
Non-refundable license fee payable annually   5,000      
UC Agreements | Maximum          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Contingent payments development milestones   3,100,000      
UC Agreements | Minimum          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Annual royalty   $ 100,000